Iovance Biotherapeutics Inc. [NASDAQ: IOVA] loss -6.48% on the last trading session, reaching $8.81 price per share at the time. The company report on October 10, 2022 that Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression.
Iovance Biotherapeutics Inc. represents 157.27 million in outstanding shares, while the company has a total market value of $1.44 billion with the latest information. IOVA stock price has been found in the range of $8.675 to $9.39.
If compared to the average trading volume of 2.27M shares, IOVA reached a trading volume of 2791013 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Iovance Biotherapeutics Inc. [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $26.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Iovance Biotherapeutics Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on August 18, 2022. While these analysts kept the previous recommendation, Stifel raised their target price from $23 to $25. The new note on the price target was released on January 28, 2022, representing the official price target for Iovance Biotherapeutics Inc. stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc. is set at 0.66 The Price to Book ratio for the last quarter was 2.93, with the Price to Cash per share for the same quarter was set at 2.60.
Trading performance analysis for IOVA stock
Iovance Biotherapeutics Inc. [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.34. With this latest performance, IOVA shares dropped by -17.59% in over the last four-week period, additionally sinking by -48.21% over the last 6 months – not to mention a drop of -66.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 39.49, with the RSI for the last a single of trading hit 38.36, and the three-weeks RSI is set at 40.66 for Iovance Biotherapeutics Inc. [IOVA]. The present Moving Average for the last 50 days of trading for this stock 10.65, while it was recorded at 9.13 for the last single week of trading, and 13.06 for the last 200 days.
Iovance Biotherapeutics Inc. [IOVA]: A deeper dive into fundamental analysis
Iovance Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.
An analysis of insider ownership at Iovance Biotherapeutics Inc. [IOVA]
There are presently around $1,401 million, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: VANGUARD GROUP INC with ownership of 13,363,027, which is approximately 8.276% of the company’s market cap and around 0.10% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 11,826,299 shares of the stock with an approximate value of $104.19 million in IOVA stocks shares; and STATE STREET CORP, currently with $103.7 million in IOVA stock with ownership of nearly 71.943% of the company’s market capitalization.
142 institutional holders increased their position in Iovance Biotherapeutics Inc. [NASDAQ:IOVA] by around 39,517,892 shares. Additionally, 124 investors decreased positions by around 37,027,724 shares, while 22 investors held positions by with 82,532,275 shares. The mentioned changes placed institutional holdings at 159,077,891 shares, according to the latest SEC report filing. IOVA stock had 39 new institutional investments in for a total of 7,063,041 shares, while 52 institutional investors sold positions of 7,572,223 shares during the same period.